4-(4-Aminophenyl)morpholin-3-One CAS 438056-69-0 Purity ≥99.0% (HPLC) Rivaroxaban Intermediate Factory

Short Description:

Chemical Name: 4-(4-Aminophenyl)morpholin-3-One

CAS: 438056-69-0

Appearance: White to Off-White Powder

Purity: ≥99.0% (HPLC)

Intermediate of Rivaroxaban (CAS: 366789-02-8) in the treatment of Venous Thromboembolism(VTE)

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply Rivaroxaban Related Intermediates:
(S)-(+)-Glycidyl Phthalimide CAS 161596-47-0
4-(4-Aminophenyl)morpholin-3-one CAS 438056-69-0
Rivaroxaban Intermediate CAS 446292-07-5
5-Chlorothiophene-2-Carboxylic Acid CAS 24065-33-6
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9
Rivaroxaban API CAS 366789-02-8

Chemical Properties:

Chemical Name	4-(4-Aminophenyl)morpholin-3-One
CAS Number	438056-69-0
CAT Number	RF-PI129
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C10H12N2O2
Molecular Weight	192.21
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Light Yellow or Light Brown Crystalline Powder
Purity / Analysis Method	≥99.0% (HPLC)
Melting Point	165.0~175.0°C
Identification	HNMR
Moisture (K.F)	≤1.0%
Loss on Drying	≤0.50%
Residue on lgnition	≤0.10%
Max Single Impurity	≤0.50%
Total Impurities	≤1.5%
Test Standard	Enterprise Standard
Usage	Rivaroxaban (CAS: 366789-02-8) Intermediate

4-(4-Aminophenyl)morpholin-3-one CAS: 438056-69-0 Synthesis Route

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

FAQ:

Application:

Ruifu Chemical is the leading manufacturer and supplier of 4-(4-Aminophenyl)morpholin-3-one (CAS: 438056-69-0) with high quality, it is an intermediate in the synthesis of Rivaroxaban (CAS: 366789-02-8). Rivaroxaban is a pure (S)-enantiomer. Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of venous thromboembolism (VTE).